|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Spatial metabolomics for evaluating response to neoadjuvant therapy in non-small cell lung cancer patients显示文摘Background:The response to neoadjuvant chemotherapy(NAC)differs substantially among individual patients with non-small cell lung cancer(NSCLC).Major pathological response(MPR)is a histomorphological read-out used to assess treatment response and prognosis in patientsNSCLC afterNAC.Although spatial metabolomics is a promising tool for evaluating metabolic phenotypes,it has not yet been utilized to assess therapy responses in patients with NSCLC.We evaluated the potential application of spatial metabolomics in cancer tissues to assess the response to NAC,using a metabolic classifier that utilizes mass spectrometry imaging combined with machine learning.Methods:Resected NSCLC tissue specimens obtained after NAC(n=88)were subjected to high-resolution mass spectrometry,and these data were used to develop an approach for assessing the response to NAC in patients with NSCLC.The specificities of the generated tumor cell and stroma classifiers were validated by applying this approach to a cohort of biologically matched chemotherapy-naive patients with NSCLC(n=85).Results:The developed tumor cell metabolic classifier stratified patients into different prognostic groups with 81.6%accuracy,whereas the stroma metabolic classifier displayed 78.4%accuracy.By contrast,the accuracies of MPR and TNM staging for stratification were 62.5%and 54.1%,respectively.The combination of metabolic and MPR classifiers showed slightly lower accuracy than either individual metabolic classifier.In multivariate analysis,metabolic classifiers were the only independent prognostic factors identified(tumor:P=0.001,hazards ratio[HR]=3.823,95%confidence interval[CI]=1.716-8.514;stroma:P=0.049,HR=2.180,95%CI=1.004-4.737),whereasMPR(P=0.804;HR=0.913;95%CI=0.445-1.874)and TNM staging(P=0.078;HR=1.223;95%CI=0.977-1.550)were not independent prognostic factors.Using Kaplan-Meier survival analyses,both tumor and stroma metabolic classifiers were able to further stratify patients as NAC responders(P<0.001)and non-responders(P<0.001).Conclusions:Our findings indicate that the metabolic constitutions of both tumor cells and the stroma are valuable additions to the classical histomorphology-based assessment of tumor response. | Jian Shen Na Sun Philipp Zens Thomas Kunzke Achim Buck Verena M.Prade Jun Wang Qian Wang Ronggui Hu Annette Feuchtinger Sabina Berezowska Axel Walch | 2022 | Cancer Communications2022，42，6： | 3 |
| 2 | Comprehensive Identification of Proteins from MALDI Imaging显示文摘 | Stefan K. Maier Hannes Hahne Amin Moghaddas Gholami Benjamin Balluff Stephan Meding Cédrik Schoene Axel K. Walch Bernhard Kuster | 2013 | Molecular & Cellular Proteomics2013，，10： | 1 |
| 3 | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing显示文摘 | Josef Rüschoff Manfred Dietel Gustavo Baretton Susanne Arbogast Axel Walch Geneviéve Monges Marie-Pierre Chenard Frédérique Penault-Llorca Iris Nagelmeier Werner Schlake H. H?fler H. H. Kreipe | 2010 | Virchows Archiv2010，，3： | 1 |
| 4 | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing显示文摘 | Josef Rüschoff Manfred Dietel Gustavo Baretton Susanne Arbogast Axel Walch Geneviéve Monges Marie-Pierre Chenard Frédérique Penault-Llorca Iris Nagelmeier Werner Schlake H. H?fler H. H. Kreipe | 2010 | Virchows Archiv2010，，3： | 1 |
| 5 | 胆酸螯合剂类降胆固醇药物研究进展显示文摘介绍多种类型胆酸螯合剂(包括带烷基季铵盐、苄基季铵盐、咪唑(?)盐活性基团的阴离子交换树脂)、在聚合物骨架和官能团间引入间隔基团的树脂以及若干新类型骨架的树脂的制备、结构特征、胆酸结合活性、降胆固醇活性等。对树脂吸附胆酸过程中的选择性和位阻作了讨论。 | 许关煜 Michael Ahlers Axel Walch | 1992 | 中国医药工业杂志1992，23，10： | 1 |
| 6 | Giant ancient schwannoma of pancreatic head treated by extended pancreatoduodenectomy显示文摘 | Ernst von Dobschuetz Axel Walch Martin Werner Ulrich T. Hopt Ulrich Adam | 2004 | Pancreatology2004，，6： | 1 |
| 7 | HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing显示文摘 | Josef Rüschoff Manfred Dietel Gustavo Baretton Susanne Arbogast Axel Walch Geneviéve Monges Marie-Pierre Chenard Frédérique Penault-Llorca Iris Nagelmeier Werner Schlake H. H?fler H. H. Kreipe | 2010 | Virchows Archiv2010，，3： | 1 |
| 8 | Proteomic and metabolic prediction of response to therapy in gastric cancer显示文摘Several new treatment options for gastric cancer have been introduced but the prognosis of patients diagnosed with gastric cancer is still poor. Disease prognosis could be improved for high-risk individuals by implementing earlier screenings. Because many patients are asymptomatic during the early stages of gastric cancer,the diagnosis is often delayed and patients present with unresectable locally advanced or metastatic disease. Cytotoxic treatment has been shown to prolong survival in general,but not all patients are responders. The application of targeted therapies and multimodal treatment has improved prognosis for those with advanced disease.However,these new therapeutic strategies do not uniformly benefit all patients.Predicting whether patients will respond to specific therapies would be of particular value and would allow for stratifying patients for personalized treatment strategies.Metabolic imaging by positron emission tomography was the first technique with the potential to predict the response of esophagogastric cancer to neoadjuvant therapy.Exploring and validating tissue-based biomarkers are ongoing processes.In this review,we discuss the status of several targeted therapies for gastric cancer,as well as proteomic and metabolic methods for investigating biomarkers for therapy response prediction in gastric cancer. | Michaela Aichler Birgit Luber Florian Lordick Axel Walch | 2014 | World Journal of Gastroenterology2014，20，38： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员